Denali Therapeutics Inc. (DNLI) Stock

About Denali Therapeutics Inc.

Denali Therapeutics Inc. (DNLI) stock trades at $18.41 with a market capitalization of $2.94B. The stock is valued at a negative price-to-earnings (P/E) ratio of -7.04, reflecting a net loss over the last twelve months, price-to-book of 4.49, price-to-sales of 880.74. Over the past 52 weeks the stock has ranged between $13.75 and $27.30, and currently trades 32.6% below its 52-week high.

On profitability, Denali Therapeutics Inc. generates a return on equity (ROE) of -55.27% (negative, reflecting a net loss), return on capital employed of -50.82%.

Denali Therapeutics Inc. by the numbers, 2016–2025

Between 2016 and 2025 Denali Therapeutics Inc. reported revenue of $0 rising to $0. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit fell to $-513.0M.

On a trailing twelve-month basis to Jun '26, revenue is $4.0M and net profit $-512.0M.

Borrowings stand at $37.0M, cash from operations was $-413.0M in the latest year, positive in 2 of the last 10.

Return on equity has averaged -32.1% over five years, and was -50.6% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Denali Therapeutics Inc. (DNLI) — frequently asked questions